In a groundbreaking revelation that could alter medical approaches to a dangerous fungal infection, a recent global study published in the esteemed journal Nature has highlighted albumin— the predominant protein found in human blood— as a formidable and previously overlooked defense mechanism against mucormycosis. This severe infection, often referred to as "black fungus," is caused by Mucorales fungi and can be fatal for nearly 50% of those affected. In some dire cases, a diagnosis of mucormycosis equates to an almost certain death sentence. The prevalence of this infection notably surged in India amid the COVID-19 pandemic, particularly impacting individuals already suffering from diabetes, compromised immune systems, or malnutrition.
The research was spearheaded by Dr. George Chamilos and his team at the University of Crete along with significant contributions from Professor Ashraf Ibrahim and his group at the Lundquist Institute for Biomedical Innovation. Their findings were striking: patients diagnosed with mucormycosis exhibited significantly lower levels of albumin compared to those with other types of fungal infections. This condition, known as hypoalbuminemia, emerged as the strongest indicator of poor health outcomes, including mortality, across diverse patient populations worldwide.
Dr. Ibrahim emphasized the importance of this discovery, stating, "This is a remarkable finding and has the potential to change the way clinicians care for mucormycosis." Essentially, the study suggests that hypoalbuminemia could serve as a crucial biomarker for identifying individuals at heightened risk for this lethal infection. By addressing this risk factor, healthcare professionals might administer albumin enriched with free fatty acids to thwart the infection proactively, which is essential given the aggressive nature of mucormycosis.
Further elucidating the role of albumin, Dr. Ibrahim noted that it plays a vital part in neutralizing key virulence factors such as toxins and other proteins produced by the fungus that contribute to tissue damage and invasive behavior within human organs. This research opens exciting possibilities for combining albumin therapy with immunotherapies aimed at Mucorales virulence factors, which the Lundquist Institute's researchers are currently exploring.
Interestingly, the study demonstrated that albumin selectively inhibits the growth of Mucorales fungi while sparing other microorganisms. When albumin was removed from healthy blood samples, the fungi thrived, indicating its protective role. Additionally, mice lacking albumin displayed heightened susceptibility to infections, whereas restoring normal albumin levels offered protection against the disease.
Delving deeper, scientists found that albumin's antifungal properties stem from fatty acids that are attached to the protein, which hinder the metabolism and protein synthesis necessary for the fungi to invade tissues and propagate disease. Blood analyses from patients suffering from mucormycosis revealed increased oxidation of these fatty acids, shedding light on the reasons behind their heightened vulnerability.
These important findings unveil a previously unexplored host-defense mechanism and suggest that therapies based on albumin could pave the way for new prevention or treatment strategies for mucormycosis, a condition with few effective treatment options available.
Source:
Pikoulas, A., et al. (2026). Albumin orchestrates a natural host defence mechanism against mucormycosis. Nature. doi: 10.1038/s41586-025-09882-3. https://www.nature.com/articles/s41586-025-09882-3
